Cargando…
Dynamin-like Protein 1 (DNML1) as a Molecular Target for Antibody-Based Immunotherapy to Treat Glaucoma
Slow and progressive loss of retinal ganglion cells (RGCs) is the main characteristic of glaucoma, the second leading cause of blindness worldwide. Previous studies have shown that impaired mitochondrial dynamics could facilitate retinal neurodegeneration. Mitochondrial dynamics are regulated direct...
Autores principales: | Tonner, Henrik, Hunn, Selina, Auler, Nadine, Schmelter, Carsten, Pfeiffer, Norbert, Grus, Franz H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9654827/ https://www.ncbi.nlm.nih.gov/pubmed/36362420 http://dx.doi.org/10.3390/ijms232113618 |
Ejemplares similares
-
A Monoclonal Anti-HMGB1 Antibody Attenuates Neurodegeneration in an Experimental Animal Model of Glaucoma
por: Tonner, Henrik, et al.
Publicado: (2022) -
Antibody and Protein Profiles in Glaucoma: Screening of Biomarkers and Identification of Signaling Pathways
por: Auler, Nadine, et al.
Publicado: (2021) -
Autoantigens in the trabecular meshwork and glaucoma‐specific alterations in the natural autoantibody repertoire
por: Beutgen, Vanessa M, et al.
Publicado: (2020) -
Synthetic antibody-derived immunopeptide provides neuroprotection in glaucoma through molecular interaction with retinal protein histone H3.1
por: Fomo, Kristian Nzogang, et al.
Publicado: (2022) -
Synthetic Polyclonal-Derived CDR Peptides as an Innovative Strategy in Glaucoma Therapy
por: Schmelter, Carsten, et al.
Publicado: (2019)